📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. (2023)

First Author: Freeman SD

Attributed to: University of Oxford – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.2023020630

PubMed Identifier: 37595359

Publication URI: http://europepmc.org/abstract/MED/37595359

Type: Journal Article/Review

Volume: 142

Parent Publication: Blood

Issue: 20

ISSN: 0006-4971